Analyst Reco. Insmed Incorporated

Equities

INSM

US4576693075

Market Closed - Nasdaq Other stock markets 21:00:00 30/04/2024 BST			5-day change	1st Jan Change
24.72 ^USD	-1.12%		-2.18%	-20.23%

04-23	Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	MT
04-11	Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	04-23	MT
Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	04-11	MT
UBS Initiates Coverage on Insmed With Buy Rating, $46 Price Target	02-27	MT
Wolfe Research Starts Insmed With Outperform Rating, $42 Price Target	02-15	MT
Mizuho Raises Price Target on Insmed to $35 From $33, Maintains Buy Rating	27/10/23	MT
Cantor Fitzgerald Increases Price Target on Insmed to $54 From $46, Maintains Overweight Rating	21/09/23	MT
Evercore ISI Adjusts Price Target on Insmed to $42 From $32, Maintains Outperform Rating	07/09/23	MT
Mizuho Securities Ups Price Target on Insmed to $33 From $30, Maintains Buy Rating	06/09/23	MT
Guggenheim Initiates Insmed With Buy Rating, $50 Price Target	26/07/23	MT
Mizuho Securities Ups Price Target on Insmed to $30 From $28, Maintains Buy Rating	26/07/23	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $46 From $49, Maintains Overweight Rating	24/02/23	MT
Barclays Adjusts Insmed Price Target to $35 From $37, Maintains Overweight Rating	20/01/23	MT
Goldman Sachs Cuts Price Target on Insmed to $39 From $44, Keeps Buy Rating	09/01/23	MT
Mizuho Initiates Insmed With Buy Rating, Sets Price Target at $28	09/12/22	MT
Barclays Starts Insmed at Overweight With $37 Price Target	07/12/22	MT
BofA Securities Starts Insmed at Buy With $39 Price Target	18/11/22	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $49 From $53, Reiterates Overweight Rating	25/10/22	MT
Cowen Adjusts Insmed's Price Target to $53 From $56, Maintains Outperform Rating	21/10/22	MT
Morgan Stanley Adjusts Price Target for Insmed to $41 From $46, Maintains Overweight Rating	14/07/22	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	01/07/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Insmed Incorporated

Equities

INSM

US4576693075

Analyst Reco.

Filters